Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Research Article

Evaluating Pharmacokinetic and Distribution Characteristics for A New Antitumor Activity Ortho-aryl Chalcone Compound of OC26 in Rats by LC-MS/MS Method

Author(s): Lexing Chen, Shiying Li, Jiang Liu, Xia Gan, Zhounan Jiang, Jun Xu* and Shaohui Cai*

Volume 17, Issue 7, 2021

Published on: 26 May, 2020

Page: [861 - 872] Pages: 12

DOI: 10.2174/1573412916999200526113828

Price: $65

Abstract

Introduction: OC26, an ortho-aryl chalcone compound, shows excellent antitumor activity in vitro and vivo. However, the pharmacokinetic characteristics of OC26 have not been comprehensively reported. It is essential to investigate the correlation of pharmacological response.

Objective: To further explore OC26, this study aims to develop an ultra-performance liquid chromatography- tandem mass spectrometric (UPLC-MS/MS) method to reveal the pharmacokinetics and distribution characteristics in rats of OC26.

Methods: An UPLC-MS/MS method was developed to detect OC26 in plasma and various tissues. The protein precipitation method was applied to process the biological samples. After intravenous injection 12.5mg/kg of OC26 in rats, plasma and tissue samples were collected from rats and the method was applied to investigate pharmacokinetic and distribution characteristics of OC26.

Results: Calibration curve samples of OC26 concentration range from 20 to 2000 ng/mL with the goodness of fit (r2> 0.99). The precisions for the method were within 12.3%, while the accuracies for the method were within ±11% (bias). The matrix effect had no influence on the accuracy and precision of the method. After intravenous injection 12.5mg/kg of OC26 in rats, OC26 was rapidly eliminated (t1/2=31.39±7.87min, MRT0→∞=15.03±2.55min) from rat plasma and widely distributed (Vd=4.83±0.96L/kg) in tissues. The highest concentration of OC26 was detected in the brain in which peak content (~8962.78ng/g at 15min) was over 5-fold higher than that of in other tissues, which prompted new potential targets in the brain. Besides, lung and heart also detected quite a high level of OC26. Benefited from quick elimination in the collected tissues and plasma, long-term accumulation was not observed as chronic toxicity might be less.

Conclusion: This UPLC-MS/MS method was successfully applied to detect OC26 and provide a theoretical basis for the further study of OC26.

Keywords: UPLC-MS/MS, OC26, ortho-aryl chalcone, pharmacokinetics, distribution, antitumor.

« Previous Next »
Graphical Abstract

[1]
Brouhard, G.J.; Rice, L.M. The contribution of αβ-tubulin curvature to microtubule dynamics. J. Cell Biol., 2014, 207(3), 323-334.
[http://dx.doi.org/10.1083/jcb.201407095] [PMID: 25385183]
[2]
Tangutur, A.D.; Kumar, D.; Krishna, K.V.; Kantevari, S. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents. Curr. Top. Med. Chem., 2017, 17(22), 2523-2537.
[http://dx.doi.org/10.2174/1568026617666170104145640] [PMID: 28056738]
[3]
Downing, K.H.; Nogales, E. Tubulin structure: insights into microtubule properties and functions. Curr. Opin. Struct. Biol., 1998, 8(6), 785-791.
[http://dx.doi.org/10.1016/S0959-440X(98)80099-7] [PMID: 9914260]
[4]
Stanton, R.A.; Gernert, K.M.; Nettles, J.H.; Aneja, R. Drugs that target dynamic microtubules: a new molecular perspective. Med. Res. Rev., 2011, 31(3), 443-481.
[http://dx.doi.org/10.1002/med.20242] [PMID: 21381049]
[5]
Bates, D.; Eastman, A. Microtubule destabilising agents: far more than just antimitotic anticancer drugs. Br. J. Clin. Pharmacol., 2017, 83(2), 255-268.
[http://dx.doi.org/10.1111/bcp.13126] [PMID: 27620987]
[6]
Zuo, Y.; Huang, J.; Zhou, B.; Wang, S.; Shao, W.; Zhu, C.; Lin, L.; Wen, G.; Wang, H.; Du, J.; Bu, X. Synthesis, cytotoxicity of new 4-arylidene curcumin analogues and their multi-functions in inhibition of both NF-kappa B and Akt signalling. Eur. J. Med. Chem., 2012, 55, 346-357.
[7]
Zuo, Y.; Yu, Y.; Wang, S.; Shao, W.; Zhou, B.; Lin, L.; Luo, Z.; Huang, R.; Du, J.; Bu, X. Synthesis and cytotoxicity evaluation of biaryl-based chalcones and their potential in TNF alpha-induced nuclear factor-kappa B activation inhibition. Eur. J. Med. Chem., 2012, 50, 393-404.
[8]
Zhu, C.; Zuo, Y.; Wang, R.; Liang, B.; Yue, X.; Wen, G.; Shang, N.; Huang, L.; Chen, Y.; Du, J.; Bu, X. Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence. J. Med. Chem., 2014, 57(15), 6364-6382.
[http://dx.doi.org/10.1021/jm500024v] [PMID: 25061803]
[9]
Zhu, C.G.; Wang, R.M.; Zheng, W.C.; Chen, D.Y.; Yue, X.; Cao, Y.N.; Qin, W.J.; Sun, H.X.; Wang, Y.Q.; Liu, Z.Y.; Li, B.J.; Du, J.; Bu, X.Z.; Zhou, B.H. Synthesis and evaluation of anticancer activity of BOC26P, an ortho-aryl chalcone sodium phosphate as water-soluble prodrugs in vitro and in vivo. Biomed. Pharmacother., 2017, 96, 551-562.
[http://dx.doi.org/10.1016/j.biopha.2017.10.006]
[10]
Xu, X.W.; Su, X.J.; Zhang, Y.N.; Zheng, X.K.; Lv, P.F.; Hu, J. Simultaneous determination of nintedanib and its metabolite BIBF 1202 in different tissues of mice by UPLC-MS/MS and its application in drug tissue distribution study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2015, 1002, 239-244.
[11]
Zhang, Q.L.; Guan, J.; Li, S.S.; Zhao, Y.L.; Yu, Z.G. Application of an UHPLC-MS/MS method to tissue distribution and excretion study of 2-(2-hydroxypropanamido) benzoic acid in rats. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2017, 1070, 54-61.
[12]
Wang, P.; Sun, J.B.; Xu, J.Y.; Yan, Q.; Gao, E.Z.; Qu, W.; Zhao, Y.L.; Yu, Z.G. Pharmacokinetics, tissue distribution and excretion study of dictamnine, a major bioactive component from the root bark of Dictamnus dasycarpus Turcz. (Rutaceae). J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2013, 942, 1-8.
[13]
Wang, Y.T.; Xie, G.; Liu, Q.; Duan, X.; Liu, Z.G.; Liu, X.B. Pharmacokinetics, tissue distribution, and plasma protein binding study of chicoric acid by HPLC-MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2016, 1031, 139-145.
[14]
Fan, A.L.; Wei, J.L.; Yang, M.R.; Zhang, Q.; Zhang, Y.L.; Liu, Q.W.; Li, N.; Zhao, D.; Lu, Y.; Li, J.X.; Zhao, J.; Deng, S.H.; Zhang, B.J.; Zhu, H.L.; Chen, X.J. Pharmacodynamic and pharmacokinetic characteristics of YMR-65, a tubulin inhibitor, in tumor-bearing mice. Eur. J. Pharm. Sci., 2018, 121, 74-84.
[http://dx.doi.org/10.1016/j.ejps.2018.05.011]
[15]
Chinese Pharmacopocia Commission. Biological sample quantitative analysis method validation guidelines. Pharmacopoeia of the People’s Republic of China IV; China Medical Science Press: Beijing, China, 2015 pp. 363-368.
[16]
US Department of Health and Human Services US Food and Drug Administration. Bioanalytical Method Validation Guidance for Industry., https://www.fda.gov/media/70858/download [Accessed on: May 18, 2019].
[17]
Wang, J.H.; Hu, S.H.; Su, J.Y.; Pan, J.P.; Mi, X.N.; Geng, H.J.; Zhang, W.; Cai, L.; Su, C.F.; Hong, A.H.; Luo, H.M. Determination of the pharmacokinetics and tissue distribution of Methyl 3,4-Dihydroxybenzoate (MDHB) in mice using liquid chromatography-tandem mass spectrometry. Eur. J. Drug Metab. Pharmacokinet., 2019, 44(2), 237-249.
[http://dx.doi.org/10.1007/s13318-018-0512-8] [PMID: 30225640]
[18]
Xiao, C.Y. Discussion on apparent distribution volume in pharmacology textbooks. Negative, 2013, 4(04), 31-32.
[19]
Pajouhesh, H.; Lenz, G.R. Medicinal chemical properties of successful central nervous system drugs. NeuroRx, 2005, 2(4), 541-553.
[20]
Alavijeh, M.S.; Chishty, M.; Qaiser, M.Z.; Palmer, A.M. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx, 2005, 2(4), 554-571.
[21]
Dallas, S.; Miller, D.S.; Bendayan, R. Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol. Rev., 2006, 58(2), 140-161.
[http://dx.doi.org/10.1124/pr.58.2.3] [PMID: 16714484]
[22]
Gribkoff, V.K.; Kaczmarek, L.K. The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes. Neuropharmacology, 2017, 120, 11-19.
[23]
Graff, C.L.; Pollack, G.M. Drug transport at the blood-brain barrier and the choroid plexus. Curr. Drug Metab., 2004, 5(1), 95-108.
[http://dx.doi.org/10.2174/1389200043489126] [PMID: 14965253]
[24]
Mikitsh, J.L.; Chacko, A-M. Pathways for small molecule delivery to the central nervous system across the blood-brain barrier. Curr. Drug Metab., 2014, 19(12), 1021-1041.
[http://dx.doi.org/10.4137/PMC.S13384]
[25]
Goncalves, J.; Bicker, J.; Alves, G.; Fortuna, A.; Falcao, A. Relevance of breast cancer resistance protein to brain distribution and central acting drugs: a pharmacokinetic perspective. Curr. Drug Metab., 2018, 19(12), 1021-1041.
[http://dx.doi.org/10.2174/1389200219666180629121033] [PMID: 29956624]

Rights & Permissions Print Cite
Article Metrics
14
1
© 2024 Bentham Science Publishers | Privacy Policy